Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia

MJ. Thorpy, I. Arnulf, N. Foldvary-Schaefer, AM. Morse, K. Šonka, P. Chandler, L. Hickey, A. Chen, J. Black, A. Sterkel, D. Chen, RK. Bogan, Y. Dauvilliers

. 2022 ; 14 (-) : 1901-1917. [pub] 20221026

Status not-indexed Language English Country New Zealand

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22031445

PURPOSE: To report the efficacy and safety of lower-sodium oxybate (LXB; Xywav®) during the open-label titration and optimization period (OLT) and stable-dose period (SDP) in a clinical study for the treatment of idiopathic hypersomnia. PATIENTS AND METHODS: Data were collected during treatment titration and optimization in a phase 3 randomized withdrawal trial in adults (18-75 years of age) with idiopathic hypersomnia who took LXB treatment (once, twice, or thrice nightly, administered orally) in the OLT (10-14 weeks), followed by the 2-week, open-label SDP. Endpoints included the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS), Patient Global Impression of Change, Clinical Global Impression of Change, Functional Outcomes of Sleep Questionnaire (FOSQ)-10, and Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP). RESULTS: The safety population included 154 participants; the modified intent-to-treat population comprised 115 participants. During open-label treatment, mean (SD) ESS scores improved (decreased) from 15.7 (3.8) at baseline to 6.1 (4.0) at end of SDP, and IHSS scores improved (decreased) from 31.6 (8.3) to 15.3 (8.5). Improvements were also observed during OLT in each individual IHSS item and in FOSQ-10 and WPAI:SHP scores. Thirty-five (22.7%) participants discontinued during OLT and SDP, 22 (14.3%) due to treatment-emergent adverse events (TEAEs) during OLT and SDP. The most frequent TEAEs in the first 4 weeks were nausea, headache, dizziness, and dry mouth; TEAE incidence decreased throughout OLT and SDP (weeks 1-4, n = 87 [56.5%]; weeks 13-16, n = 39 [31.7%]). CONCLUSION: During open-label treatment with LXB, participants showed clinically meaningful improvements in idiopathic hypersomnia symptoms and in quality of life and functional measures. TEAE incidence declined over LXB titration and optimization.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031445
003      
CZ-PrNML
005      
20230127131154.0
007      
ta
008      
230119s2022 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/NSS.S369122 $2 doi
035    __
$a (PubMed)36320423
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Thorpy, Michael J $u Albert Einstein College of Medicine, Bronx, NY, USA $1 https://orcid.org/0000000239932230
245    10
$a Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia / $c MJ. Thorpy, I. Arnulf, N. Foldvary-Schaefer, AM. Morse, K. Šonka, P. Chandler, L. Hickey, A. Chen, J. Black, A. Sterkel, D. Chen, RK. Bogan, Y. Dauvilliers
520    9_
$a PURPOSE: To report the efficacy and safety of lower-sodium oxybate (LXB; Xywav®) during the open-label titration and optimization period (OLT) and stable-dose period (SDP) in a clinical study for the treatment of idiopathic hypersomnia. PATIENTS AND METHODS: Data were collected during treatment titration and optimization in a phase 3 randomized withdrawal trial in adults (18-75 years of age) with idiopathic hypersomnia who took LXB treatment (once, twice, or thrice nightly, administered orally) in the OLT (10-14 weeks), followed by the 2-week, open-label SDP. Endpoints included the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS), Patient Global Impression of Change, Clinical Global Impression of Change, Functional Outcomes of Sleep Questionnaire (FOSQ)-10, and Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP). RESULTS: The safety population included 154 participants; the modified intent-to-treat population comprised 115 participants. During open-label treatment, mean (SD) ESS scores improved (decreased) from 15.7 (3.8) at baseline to 6.1 (4.0) at end of SDP, and IHSS scores improved (decreased) from 31.6 (8.3) to 15.3 (8.5). Improvements were also observed during OLT in each individual IHSS item and in FOSQ-10 and WPAI:SHP scores. Thirty-five (22.7%) participants discontinued during OLT and SDP, 22 (14.3%) due to treatment-emergent adverse events (TEAEs) during OLT and SDP. The most frequent TEAEs in the first 4 weeks were nausea, headache, dizziness, and dry mouth; TEAE incidence decreased throughout OLT and SDP (weeks 1-4, n = 87 [56.5%]; weeks 13-16, n = 39 [31.7%]). CONCLUSION: During open-label treatment with LXB, participants showed clinically meaningful improvements in idiopathic hypersomnia symptoms and in quality of life and functional measures. TEAE incidence declined over LXB titration and optimization.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Arnulf, Isabelle $u Sleep Disorder Unit, Pitié-Salpêtrière Hospital and Sorbonne University, Paris, France $1 https://orcid.org/0000000222402516
700    1_
$a Foldvary-Schaefer, Nancy $u Cleveland Clinic Sleep Disorders Center, Department of Neurology, Lerner College of Medicine, Cleveland, OH, USA
700    1_
$a Morse, Anne Marie $u Janet Weis Children's Hospital, Geisinger, Danville, PA, USA $1 https://orcid.org/0000000344940195
700    1_
$a Šonka, Karel $u Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000157739656
700    1_
$a Chandler, Patricia $u Jazz Pharmaceuticals, Palo Alto, CA, USA
700    1_
$a Hickey, Luke $u Jazz Pharmaceuticals, Philadelphia, PA, USA $1 https://orcid.org/0000000286919936
700    1_
$a Chen, Abby $u Jazz Pharmaceuticals, Palo Alto, CA, USA
700    1_
$a Black, Jed $u Jazz Pharmaceuticals, Palo Alto, CA, USA $u Stanford University Center for Sleep Sciences and Medicine, Palo Alto, CA, USA $1 https://orcid.org/0000000228122435
700    1_
$a Sterkel, Amanda $u Jazz Pharmaceuticals, Palo Alto, CA, USA
700    1_
$a Chen, Dan $u Formerly Jazz Pharmaceuticals, Palo Alto, CA, USA
700    1_
$a Bogan, Richard K $u University of South Carolina School of Medicine, Columbia, SC, USA $1 https://orcid.org/0000000170432974
700    1_
$a Dauvilliers, Yves $u Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France $u University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier, France $1 https://orcid.org/0000000306836506
773    0_
$w MED00189562 $t Nature and science of sleep $x 1179-1608 $g Roč. 14, č. - (2022), s. 1901-1917
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36320423 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131146 $b ABA008
999    __
$a ok $b bmc $g 1889500 $s 1182778
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 14 $c - $d 1901-1917 $e 20221026 $i 1179-1608 $m Nature and science of sleep $n Nat. sci. sleep $x MED00189562
LZP    __
$a Pubmed-20230119

Find record

Citation metrics

Archiving options